Analgesics
Antiandrogens
Antihistamines
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All colchicine studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchColchicineColchicine (more..)
Melatonin Meta
Metformin Meta
Antihistamines Meta
Azvudine Meta Molnupiravir Meta
Bromhexine Meta
Budesonide Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Paxlovid Meta
Famotidine Meta Quercetin Meta
Favipiravir Meta Remdesivir Meta
Fluvoxamine Meta Thermotherapy Meta
Hydroxychlor.. Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

The Potential Role of Colchicine in Reducing Mortality and Mechanical Ventilation Rates in COVID-19 Infection: A Meta-analysis

Rai et al., Journal of Advances in Medicine and Medical Research, doi:10.9734/jammr/2022/v34i2031503
Jul 2022  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Mortality 37% Improvement Relative Risk Colchicine for COVID-19  Rai et al.  META ANALYSIS c19early.org Favorscolchicine Favorscontrol 0 0.5 1 1.5 2+
Colchicine for COVID-19
5th treatment shown to reduce risk in September 2020
 
*, now with p = 0.00000031 from 56 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,400+ studies for 79 treatments. c19early.org
Meta analysis of 12 colchicine studies, showing significantly lower mortality with treatment.
10 meta analyses show significant improvements with colchicine for mortality1-8, oxygen therapy8, hospitalization9, and severity10.
Currently there are 56 colchicine for COVID-19 studies, showing 28% lower mortality [17‑37%], 29% lower ventilation [-15‑56%], 34% lower ICU admission [8‑52%], 19% lower hospitalization [11‑26%], and 9% more cases [-8‑29%].
risk of death, 37.0% lower, RR 0.63, p = 0.001.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Rai et al., 27 Jul 2022, peer-reviewed, 15 authors. Contact: iqra.mukhtar@live.com.
This PaperColchicineAll
The Potential Role of Colchicine in Reducing Mortality and Mechanical Ventilation Rates in COVID-19 Infection: A Meta-analysis
Shilpa Rai, Shahbaz Singh Nijjar, Blessing T. Ojinna, Iqra Mukhtar, Maryam Ahmed, Opeyemi Tobalesi, Prerna Singh, Olamide Adefashola, Abiodun O. Aboaba, Danish Waqar, Jeffrey Ndove, Frederick Ferguson, Adewale Mark Adedoyin, Patrick Batti, Hammad Zafar
Journal of Advances in Medicine and Medical Research, doi:10.9734/jammr/2022/v34i2031503
Background: Colchicine is one of many drugs being repurposed for COVID-19 due to its potential as an anti-inflammatory agent alongside its easy accessibility and oral administration. This study aims to identify the risk reduction in mortality and mechanical ventilation of colchicine-treated COVID-19 patients compared to the standard of care/placebo. Methods: A systematic search was conducted until December 31, 2021, with keywords including Colchicine, COVID-19, SARS-CoV-2, anti-inflammatory, trials, clinical, mechanical ventilation, death, and mortality. Databases including MEDLINE/PubMed, Scopus, Web of Science, CINAHL Plus, Cochrane, WHO Global Database, and Preprint servers were searched. Using dichotomous data for all values, the risk ratios (RR) were calculated by applying the random-effects model in Review Manager 5.4. Results: The 12 studies pooled 17,297 participants, with 8,528 patients in the colchicine group and 8,769 in the standard care group. Colchicine treatment led to a statistically significant reduction in the risk of death (RR=0.63, 95% CI=0.48-0.84, P=0.001). Moderately high heterogeneity was present among the included studies (I 2 =72%). While insignificant, the risk of mechanical ventilation was decreased by 12% among the colchicine group (RR=0.88, 95% CI=0.64-1.22, P=0.44). Conclusions: While this meta-analysis finds overall reductions in mortality with colchicine treatment, these findings must be utilized with caution. Placebo-controlled randomized clinical trials are warranted at a large scale to validate the viability of colchicine as an adjuvant treatment for COVID-19. On obtaining more concrete findings, the potential role of colchicine may be better optimized in non-severe patients as well, across in-hospital and outpatient settings.
References
Brunetti, Diawara, Tsai, Colchicine to Weather the Cytokine Storm in Hospitalized Patients with COVID-19, J Clin Med, doi:10.3390/jcm9092961
García-Posada, Vesga, Mestra, Clinical outcomes of patients hospitalized for COVID-19 and evidence-based on the pharmacological management reduce mortality in a region of the Colombian Caribbean, J Infect Public Health, doi:10.1016/j.jiph.2021.02.013
Mahale, Rajhans, Godavarthy, A Retrospective Observational Study of Hypoxic COVID-19 Patients Treated with Immunomodulatory Drugs in a Tertiary Care Hospital, Indian J Crit Care Med, doi:10.5005/jp-journals-10071-23599
Manenti, Maggiore, Fiaccadori, Reduced mortality in COVID-19 patients treated with colchicine: Results from a retrospective, observational study, PLoS One, doi:10.1371/journal.pone.0248276
Mori, Taki, Wakabayashi, Colchicine treatment early after infarction attenuates myocardial inflammatory response demonstrated by 14 C-methionine imaging and subsequent ventricular remodeling by quantitative gated SPECT, Ann Nucl Med, doi:10.1007/s12149-020-01559-3
Pascart, Richette, Colchicine in Gout: An Update, Curr Pharm Des, doi:10.2174/13816128249991801151039
Reyes, Hu, Teperman, Antiinflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Reyes, Hu, Teperman, Antiinflammatory therapy for COVID-19 infection: the case for colchicine, Ann Rheum Dis, doi:10.1136/annrheumdis-2020-219174
Romagnoli, Peris, Gaudio, Geppetti, SARS-CoV-2 and COVID-19: From the Bench to the Bedside, Physiol Rev, doi:10.1152/physrev.00020.2020
Sandhu, Tieng, Chilimuri, Franchin, A Case Control Study to Evaluate the Impact of Colchicine on Patients Admitted to the Hospital with Moderate to Severe COVID-19 Infection, Can J Infect Dis Med Microbiol, doi:10.1155/2020/8865954
Stewart, Yang, Atkins, Adverse events during oral colchicine
Van Echteld, Wechalekar, Schlesinger, Buchbinder, Aletaha, Colchicine for acute gout, Cochrane Database Syst Rev, doi:10.1002/14651858.CD006190.pub2
Vrachatis, Giannopoulos, Giotaki, Impact of colchicine on mortality in patients with COVID-19: A meta
Xia, Yang, Qian, Meta-analysis Evaluating the Utility of Colchicine in Secondary Prevention of Coronary Artery Disease, Am J Cardiol, doi:10.1016/j.amjcard.2020.10.043
{ 'indexed': {'date-parts': [[2022, 7, 30]], 'date-time': '2022-07-30T05:13:00Z', 'timestamp': 1659157980483}, 'reference-count': 0, 'publisher': 'Sciencedomain International', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'abstract': '<jats:p>Background: Colchicine is one of many drugs being repurposed for COVID-19 due to its ' 'potential as an anti-inflammatory agent alongside its easy accessibility and oral ' 'administration. This study aims to identify the risk reduction in mortality and mechanical ' 'ventilation of colchicine-treated COVID-19 patients compared to the standard of ' 'care/placebo.&#x0D;\n' 'Methods: A systematic search was conducted until December 31, 2021, with keywords including ' 'Colchicine, COVID-19, SARS-CoV-2, anti-inflammatory, trials, clinical, mechanical ' 'ventilation, death, and mortality. Databases including MEDLINE/PubMed, Scopus, Web of ' 'Science, CINAHL Plus, Cochrane, WHO Global Database, and Preprint servers were searched. ' 'Using dichotomous data for all values, the risk ratios (RR) were calculated by applying the ' 'random-effects model in Review Manager 5.4.&#x0D;\n' 'Results: The 12 studies pooled 17,297 participants, with 8,528 patients in the colchicine ' 'group and 8,769 in the standard care group. Colchicine treatment led to a statistically ' 'significant reduction in the risk of death (RR=0.63, 95% CI=0.48-0.84, P=0.001). Moderately ' 'high heterogeneity was present among the included studies (I2=72%). While insignificant, the ' 'risk of mechanical ventilation was decreased by 12% among the colchicine group (RR=0.88, 95% ' 'CI=0.64-1.22, P=0.44).&#x0D;\n' 'Conclusions: While this meta-analysis finds overall reductions in mortality with colchicine ' 'treatment, these findings must be utilized with caution. Placebo-controlled randomized ' 'clinical trials are warranted at a large scale to validate the viability of colchicine as an ' 'adjuvant treatment for COVID-19. On obtaining more concrete findings, the potential role of ' 'colchicine may be better optimized in non-severe patients as well, across in-hospital and ' 'outpatient settings.</jats:p>', 'DOI': '10.9734/jammr/2022/v34i2031503', 'type': 'journal-article', 'created': {'date-parts': [[2022, 7, 30]], 'date-time': '2022-07-30T04:40:59Z', 'timestamp': 1659156059000}, 'page': '349-358', 'source': 'Crossref', 'is-referenced-by-count': 0, 'title': 'The Potential Role of Colchicine in Reducing Mortality and Mechanical Ventilation Rates in ' 'COVID-19 Infection: A Meta-analysis', 'prefix': '10.9734', 'author': [ {'given': 'Shilpa', 'family': 'Rai', 'sequence': 'first', 'affiliation': []}, {'given': 'Shahbaz Singh', 'family': 'Nijjar', 'sequence': 'first', 'affiliation': []}, {'given': 'Blessing', 'family': 'T. OJinna', 'sequence': 'first', 'affiliation': []}, {'given': 'Iqra', 'family': 'Mukhtar', 'sequence': 'first', 'affiliation': []}, {'given': 'Maryam', 'family': 'Ahmed', 'sequence': 'first', 'affiliation': []}, {'given': 'Opeyemi', 'family': 'Tobalesi', 'sequence': 'first', 'affiliation': []}, {'given': 'Prerna', 'family': 'Singh', 'sequence': 'first', 'affiliation': []}, {'given': 'Olamide', 'family': 'Adefashola', 'sequence': 'first', 'affiliation': []}, {'given': 'Abiodun', 'family': 'O. Aboaba', 'sequence': 'first', 'affiliation': []}, {'given': 'Danish', 'family': 'Waqar', 'sequence': 'first', 'affiliation': []}, {'given': 'Jeffrey', 'family': 'Ndove', 'sequence': 'first', 'affiliation': []}, {'given': 'Frederick', 'family': 'Ferguson', 'sequence': 'first', 'affiliation': []}, {'given': 'Adewale Mark', 'family': 'Adedoyin', 'sequence': 'first', 'affiliation': []}, {'given': 'Patrick', 'family': 'Batti', 'sequence': 'first', 'affiliation': []}, {'given': 'Hammad', 'family': 'Zafar', 'sequence': 'first', 'affiliation': []}], 'member': '4694', 'published-online': {'date-parts': [[2022, 7, 27]]}, 'container-title': 'Journal of Advances in Medicine and Medical Research', 'original-title': [], 'link': [ { 'URL': 'https://journaljammr.com/index.php/JAMMR/article/download/31503/59027', 'content-type': 'application/pdf', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journaljammr.com/index.php/JAMMR/article/download/31503/59028', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'text-mining'}, { 'URL': 'https://journaljammr.com/index.php/JAMMR/article/download/31503/59027', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2022, 7, 30]], 'date-time': '2022-07-30T04:41:00Z', 'timestamp': 1659156060000}, 'score': 1, 'resource': {'primary': {'URL': 'https://journaljammr.com/index.php/JAMMR/article/view/31503'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2022, 7, 27]]}, 'references-count': 0, 'URL': 'http://dx.doi.org/10.9734/jammr/2022/v34i2031503', 'relation': {}, 'ISSN': ['2456-8899'], 'subject': ['General Medicine'], 'container-title-short': 'JAMMR', 'published': {'date-parts': [[2022, 7, 27]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit